Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Atea Pharmaceuticals, Inc. (AVIR)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
5.80-0.19 (-3.17%)
At close: 04:00PM EDT
6.00 +0.20 (+3.45%)
After hours: 07:42PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Inside Bar (Bullish)

Inside Bar (Bullish)

Previous Close5.99
Open5.88
Bid5.58 x 900
Ask6.24 x 1100
Day's Range5.61 - 5.94
52 Week Range5.31 - 46.91
Volume862,497
Avg. Volume439,652
Market Cap482.9M
Beta (5Y Monthly)N/A
PE Ratio (TTM)48.33
EPS (TTM)0.12
Earnings DateNov 09, 2022 - Nov 14, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est9.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Undervalued
89% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for AVIR

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Atea Pharmaceuticals, Inc.
    Daily – Vickers Top Buyers & Sellers for 08/23/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    last monthArgus Research
View more
  • Benzinga

    Atea Pharmaceuticals To Advance Global Late-Stage COVID-19 Study of Bemnifosbuvir

    Atea Pharmaceuticals Inc (NASDAQ: AVIR) announced additional details on its clinical development plans for bemnifosbuvir for COVID-19. Following meetings with the FDA and the European Medicines Agency Emergency Task Force, Atea plans to initiate a global Phase 3 trial of bemnifosbuvir for COVID-19 in the fourth quarter of 2022. The trial will evaluate bemnifosbuvir as both monotherapy and combination antiviral therapy in outpatients (non-hospitalized) with COVID-19 who are at the highest risk of

  • GlobeNewswire

    Atea to Advance Global Phase 3 Registrational Study of Bemnifosbuvir in High-Risk Non-Hospitalized Patients with COVID-19

    Novel Phase 3 Trial Design to Evaluate Bemnifosbuvir as Monotherapy and Combination Antiviral Therapy for COVID-19 Trial to Focus on High-Risk Patients at Greatest Risk for Disease Progression Trial Expected to Initiate in Fourth Quarter 2022 Conference Call at 8:30 a.m. ET Today BOSTON, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced additional details on its clinical development plans for bemnifo

  • GlobeNewswire

    Atea Pharmaceuticals Announces Upcoming Investor Events

    BOSTON, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that Atea management will participate in the following investor events in September. Bemnifosbuvir Global Phase 3 Registrational Trial in Non-Hospitalized Patients: Company management will host a conference call on Tuesday, September 13, 2022 at 8:30 a.m. ET to provide details on the study design of the global Phase 3 registrational trial of b

Advertisement
Advertisement